47 related articles for article (PubMed ID: 25093184)
1. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy.
Wang C; Huang M; Lin Y; Zhang Y; Pan J; Jiang C; Cheng M; Li S; He W; Li Z; Tu Z; Fan J; Zeng H; Lin J; Wang Y; Yao N; Liu T; Qi Q; Liu X; Zhang Z; Chen M; Xia L; Zhang D; Ye W
Nat Metab; 2023 Oct; 5(10):1765-1786. PubMed ID: 37667133
[TBL] [Abstract][Full Text] [Related]
2. Depiction of neuroendocrine features associated with immunotherapy response using a novel one-class predictor in lung adenocarcinoma.
Liu H; Han Y; Liu Z; Gao L; Yi T; Yu Y; Wang Y; Qu P; Xiang L; Li Y
Discov Oncol; 2023 May; 14(1):71. PubMed ID: 37199872
[TBL] [Abstract][Full Text] [Related]
3. Is neuroendocrine differentiation a prognostic factor in poorly differentiated colorectal cancer?
Chen Y; Liu F; Meng Q; Ma S
World J Surg Oncol; 2017 Mar; 15(1):71. PubMed ID: 28351413
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine-like cells -derived CXCL10 and CXCL11 induce the infiltration of tumor-associated macrophage leading to the poor prognosis of colorectal cancer.
Zeng YJ; Lai W; Wu H; Liu L; Xu HY; Wang J; Chu ZH
Oncotarget; 2016 May; 7(19):27394-407. PubMed ID: 27034164
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation: The mysterious fellow of colorectal cancer.
Kleist B; Poetsch M
World J Gastroenterol; 2015 Nov; 21(41):11740-7. PubMed ID: 26556999
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of neuroendocrine differentiation in colorectal adenocarcinoma after radical operation: a meta-analysis.
Zeng YJ; Lai W; Liu L; Wu H; Luo XX; Wang J; Chu ZH
J Gastrointest Surg; 2014 May; 18(5):968-76. PubMed ID: 24549474
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation is a prognostic factor for stage II poorly differentiated colorectal cancer.
Liu Y; Xu J; Jiao Y; Hu Y; Yi C; Li Q; Tong Z; Wang X; Hu L; Xiao Q; Li J; Ding K
Biomed Res Int; 2014; 2014():789575. PubMed ID: 25093184
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation is predictive of poor survival in patients with stage II colorectal cancer.
Liu Y; He J; Xu J; Li J; Jiao Y; Bei D; Hu Y; Chen H; Xiao Q; Ding K
Oncol Lett; 2017 Apr; 13(4):2230-2236. PubMed ID: 28454385
[TBL] [Abstract][Full Text] [Related]
10. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine-like differentiation in patients with pancreatic carcinoma.
Tezel E; Nagasaka T; Nomoto S; Sugimoto H; Nakao A
Cancer; 2000 Dec; 89(11):2230-6. PubMed ID: 11147593
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
